Clinical Trial Update: TMC435350-TiDP16-C101 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of Increasing Oral Doses of TMC435350 After Single and Repeated Dosing [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating safety, tolerability and pharmacokinetics of increasing oral doses of TMC435350 after single and repeated dosing in Hepatitis C.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• TMC435350

Snippet

Sponsor: Tibotec Pharmaceuticals, Ireland | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED